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Plasmacytomas are localized neoplastic proliferation of
plasma cells. They are usually solitary and may occasionally
be the only manifestation in multiple myeloma. The upper res-
piratory tract is the commonest extramedullary site. The site of
the lesion dictates the symptoms. Cranial nerve involvement,
secondary to cranial plasmacytomas is uncommon. We present
a case of advanced myeloma, whose sole presenting symptoms
were vertigo and hearing loss secondary to cranial
plasmacytomas.
Case report
A 54-year-old lady with dizziness and left side hearing loss (for
3 months), who was being treated as benign positional periph-
eral vertigo with betahistine, was referred to our center on
account of progression of her symptoms. Clinical examination
was normal except for left sensory neural deafness. MRI brain
revealed multiple lytic lesions in the skull with homogenously
enhancing soft tissue component, largest (3.8  2.9 cm) involv-
ing left occipital condoyle and occipital bone (Figs. 1 and 2). A
skeletal survey showed multiple calvarial lytic lesions. Hemato-
logical investigations revealed elevated ESR (>100) with nor-
mal cell counts. Serum biochemistry was normal. Serum
protein profile revealed altered albumin globulin ratio, normalserum immunoglobulins, elevated free lambda light chain
(800.7 mg/dl) with low free kappa / lambda ratio (0.02) and
immune fixation electrophoresis confirmed lambda mono-
clonal gammopathy. Urine was positive for Bence-Jones pro-
tein and 24 h urinary protein excretion was 787 mg/day.
Serum Beta 2 micro globulin was 2.3 mg/L. Bone marrow
examination was suggestive of Myeloma and she was diag-
nosed to have Lambda light chain multiple myeloma ISS
stage-1. She was administered pulse steroids (dexamethasone
40 mg IV for four days) and her symptoms improved dramat-
ically. She was started on bortezomib, lenalidomide and dex-
amethasone chemotherapy. (Bortezomib 2 mg IV on days 1,
8, 15 and 22 plus lenalidomide 20 mg PO daily on days 1–21
plus dexamethasone 40 mg PO daily on days 1, 8, 15, and
22; Q 28 d cycle). She received 6 cycles of chemotherapy. She
attained very good response status (normal serum
immunoglobulins and normal serum electrophoresis pattern)
and is at present on lenalidomide maintenance. (20 mg PO
daily on days 1–21; Q 28 d cycle).
Discussion
Multiple bone pains, renal impairment, hypercalcemia, infec-
tions and marrow failure are common presentations of Mye-
loma. Plasmacytomas result from localized neoplastic plasma
cell proliferation. The location of plasmacytoma dictates the
symptoms, and upper respiratory tract is the commonest extra-
medullary site. Solitary bone and extramedullary plasmacy-
tomas account for 3–5% of plasma cell neoplasms [1,2].
Subjects with bone plasmacytomas present with pain or patho-
logic fracture. Less than 1% head and neck tumours [3] are
plasmacytomas, and 80% occur in the nasopharynx and para-t (2016),
Figure 1 MRI brain (axial) shows homogenously enhancing soft
tissue component involving left occipital condoyle and occipital
bone.
Figure 2 MRI brain (coronal) shows homogenously enhancing
soft tissue component involving left occipital condoyle and
occipital bone.
2 K. Rakul Nambiar et al.nasal sinuses [4]. Plasmacytomas of the skull base are usually
asymptomatic. Wein et al. [5] divided them into anterior
(nasopharyngeal) and central (sphenoid, clivus, petrous apex)
group and noted that 63.6% of central and only 9.5% of ante-
rior group progressed to myeloma.
Cranial nerve involvement is rare in skull base plasmacy-
tomas. The neuropathy occurs due to compression of the cra-
nial nerve or nerve groups along their intracranial route or at
their outlets in the skull base. The abducens nerve is the most
frequent cranial nerve affected because of its long intracranial
course [6]. The other commonly affected cranial nerves are II
and III [6,7]. Cranial nerves like IX, X, XII [8,9] have been
rarely affected in very large tumors. Most of these cases were
reported in multiple myeloma patients who developed associ-
ated intracranial plasmacytoma [6–10]. Patients with multiple
myeloma and associated intracranial plasmacytoma are trea-
ted with localized radiotherapy followed by systemic
chemotherapy. Radiation therapy has excellent local control
of solitary plasmacytomas. However, the optimal radiation
dose for treatment of solitary plasmacytomas is not known.
The median dose used in most published papers is 40 Gy with
doses ranging from 30 to 60 Gy [11–13]. For patients treated
with surgical excision, radiotherapy is still indicated to eradi-
cate microscopic residual disease. Surgery alone without radio-
therapy leads to an unacceptably high local recurrence rate
[14]. For patients with osseous plasmacytoma, NCCN Panel
recommends primary radiation therapy (>30 Gy to thePlease cite this article in press as: Rakul Nambiar K et al. Vertigo and deafness: The
http://dx.doi.org/10.1016/j.jnci.2016.09.001involved field) to the involved field as the initial treatment
and is potentially curative. For patients with extraosseous
plasmacytomas, primary treatment is radiation therapy
(>30 Gy to the involved field) to the involved field followed
by surgery if necessary. Hence treatable skull base plasmacy-
tomas must be considered in the differential diagnosis of
patients who present with multiple or single cranial
neuropathy.
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